Cogent Biosciences, Inc. (COGT) Stock: Price, Forecast & Analyst Target
Cogent Biosciences, Inc. (COGT) — MoonshotScore 53/100 (Fair band), calculated Oct 5, 2026. Price $31.02 (-1.80%), as of the Oct 2, 2026 trading session; market cap $5.30B. Expected results Nov 6, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 6.69× (market value Oct 2, 2026; cash Jun 30, 2026) · expected results Nov 6, 2026
Cogent Biosciences, Inc. · COGT · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: Cogent Biosciences is a clinical-stage biotechnology company developing targeted therapies for genetic mutations that drive blood and gastrointestinal cancers, with its lead candidate in late-stage trials. The central question is whether the lead program advances to regulatory approval and commercial launch, generating revenue that transitions the company from burn-rate dependent to cash-generative; if the program fails, cash runway becomes the critical metric.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore v2 · Cogent Biosciences (COGT)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Weak quality and weak growth; the market is already moving on it. Business Quality: Thin; Financial Safety: Okay; Valuation: Full; Growth Durability: Fading; Momentum: Rising.
- quarterly revenue $0 (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 4 of 8
- Altman Z 7.79 · Piotroski F 2
Holding back: soft growth
Helping: positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 53 | Fair | |
| 53 | Fair | |
| 53 | Fair | |
| 53 | Fair | |
| 53 | Fair | |
| 53 | Fair |
The score was 53 in the stored Oct 4, 2026 snapshot and remains 53 in the current publication computed Oct 5, 2026 (0); the largest pillar moves were Growth Durability +4; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $31.02 |
| Change on the day | -1.80% |
| 52-week range | $13.78–$43.73 |
| Market capitalisation | $5.30B |
| Price / earnings (trailing) | -37.99 |
| Shares traded on the day | 1.17M |
| Beta (volatility vs the S&P 500) | 0.31 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · in line with the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
The provider's estimated date can change.
What to watch nextOther perspectives
Council score for Cogent Biosciences (COGT): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 19, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the COGT film — every key number, told as a short cinematic story
~2 min · open the film
What is Cogent Biosciences (COGT), and what does it report?
Short answer · as of
Cogent does not sell products and generates no revenue.
Research dated 2026-09-13.
Cogent does not sell products and generates no revenue. It is a development-stage company that executes research and clinical trials, burning through cash as it tests whether its targeted therapies work and are safe enough for regulatory approval.
The financial statements show research and development expenses as the primary operating cost, plus overhead for corporate and support functions. Without revenue, every metric—gross margin, operating margin, returns on assets—is negative by definition. The only metric that matters is cash runway and the likelihood that the lead program advances.
What do the latest results show for Cogent Biosciences (COGT)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $0.
Research dated 2026-09-13.
The company continues to report operating losses each quarter, as expected for an unfunded clinical-stage program. The operating cash burn rate has been steady, suggesting the company is executing its development timeline without major setbacks or accelerations.
There are no revenue or earnings surprises at a company with no revenue. The signal lies in whether the company announces clinical trial progress, regulatory meetings, or partnership achievements that reduce execution risk. Management guidance on cash runway is the most relevant metric.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · R&D
- $70.81M Jun 30, 2026
- Latest quarter · SG&A
- $31.83M Jun 30, 2026
- Latest quarter · FMP standardized operating result
- −$102.64M Jun 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | Not available | $70.81M | $31.83M | −$102.64M |
| Mar 31, 2026 | Not available | $75.36M | $28.24M | −$103.61M |
| Dec 31, 2025 | Not available | $74.38M | $23.93M | −$99.49M |
| Sep 30, 2025 | Not available | $68.99M | $14.37M | −$83.36M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue estimate
- $1,000 Aug 10, 2026
- Latest report · EPS vs estimate
- Above estimate Aug 10, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 10, 2026 | Not available | $1,000 | −$0.5200 | −$0.5550 |
| May 5, 2026 | Not available | $500.00 | −$0.5300 | −$0.5300 |
| Feb 17, 2026 | Not available | Provider row rejected | −$0.5500 | −$0.5100 |
| Nov 7, 2025 | Not available | Not available | −$0.5000 | −$0.5400 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $0 | -$96M | -$0.56 (diluted) |
| Q1 FY2026 | $0 | -$97M | -$0.57 (diluted) |
| Q4 FY2025 | $0 | -$102M | -$0.64 (diluted) |
| Q3 FY2025 | $0 | -$81M | -$0.58 (diluted) |
What are the financial strengths and risks for Cogent Biosciences (COGT)?
Short answer
Cash and short-term investments were $792.30M at the Jun 30, 2026 balance-sheet date. Operating cash flow was −$77.27M for the quarter ended Jun 30, 2026, meaning operations used cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
The company maintains a substantial cash balance sufficient to fund operations for multiple years at the current burn rate. However, cash is finite; once depleted, the company must either achieve financing through equity issuance, debt, or partnership with a larger pharmaceutical company.
The risk is not imminent insolvency but dilution to shareholders if the company must raise capital at unfavorable terms. A major clinical setback could accelerate the burn rate, shortening runway. The company has debt, which would be senior to equity in a restructuring.
Data-derived red flags
- Negative return on equity (-85.7%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- −$77.27M Jun 30, 2026
- Previous quarter · operating cash flow
- −$86.88M Mar 31, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 30, 2026 | −$77.27M | −$370,000 |
| Mar 31, 2026 | −$86.88M | −$450,000 |
| Dec 31, 2025 | −$79.10M | −$810,000 |
| Sep 30, 2025 | −$64.29M | −$60,000 |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at Cogent Biosciences (COGT)?
Short answer · as of
The next earnings report is expected on Nov 6, 2026.
Research dated 2026-09-13.
Watch for announcements from the lead clinical trial: interim data results, dosing decisions, or regulatory feedback. Any material update is a catalyst for stock repricing and a signal of whether the program remains viable.
Monitor cash balance trends and any announcement of financing activity, partnership, or licensing arrangements. Such announcements would alter the runway calculation and capital structure.
How does Cogent Biosciences compare with its peers?
Short answer
Cogent Biosciences's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Cogent differs from commercial pharma companies by having no approved products, no manufacturing scale, and no sales infrastructure. Its value depends entirely on the probability that its lead program succeeds and the estimated commercial opportunity if it does.
Against other clinical-stage biotech, Cogent's value relative to cash runway depends on the quality of its trial data and the magnitude of unmet medical need in its target populations. Investors are betting on clinical success probability and magnitude of future market opportunity, not on current operations.
| Company | Price | Market value | Score |
|---|---|---|---|
| $302.96 Oct 2, 2026 | $6.07B | 96 5-pillar Oct 5, 2026 | |
| $46.52 Oct 5, 2026 | $3.71B | 96 5-pillar Oct 5, 2026 | |
| $28.30 Oct 2, 2026 | $8.00B | 89 5-pillar Oct 5, 2026 | |
| $25.16 Oct 2, 2026 | $3.15B | 88 5-pillar Oct 5, 2026 | |
| $19.95 Oct 2, 2026 | $3.42B | 76 5-pillar Oct 5, 2026 | |
| $140.06 Oct 2, 2026 | $9.01B | 75 5-pillar Oct 5, 2026 | |
| $46.97 Oct 2, 2026 | $3.36B | 73 5-pillar Oct 5, 2026 | |
| $159.73 Oct 5, 2026 | $6.40B | 69 5-pillar Oct 5, 2026 | |
| $84.52 Oct 2, 2026 | $5.10B | 68 5-pillar Oct 5, 2026 | |
| $41.40 Oct 2, 2026 | $4.45B | 66 5-pillar Oct 5, 2026 | |
| $54.29 Oct 2, 2026 | $8.31B | 65 5-pillar Oct 5, 2026 | |
| $116.76 Oct 2, 2026 | $4.88B | 64 5-pillar Oct 5, 2026 | |
| Cogent Biosciences (COGT) — this page | $31.02 | $5.30B | 53 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $45.00 – $55.00
- Consensus target
- $51.75
- Median target
- $53.50
Consensus record · Captured .
Measured against a quoted price of $31.02 (as of Oct 2, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Aug 27, 2026
- Transactions
- 15
- Identified insiders
- 7
- Purchases
- 0
- Sales
- 2
- Other transactions
- 13
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Reporting holders
- 336 Period end Jun 30, 2026
- Previous quarter · holders
- 317 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Fmr LLC | 25,681,174 |
| Blackrock, INC. | 17,352,646 |
| Vanguard Portfolio Management LLC | 8,072,411 |
| Vanguard Capital Management LLC | 7,412,330 |
| State Street Corp | 6,964,919 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Cogent Biosciences (COGT)?
- Here’s How Much You Would Have Made Owning Cogent Biosciences Stock In The Last 5 Years
- Cogent Biosciences Gets US FDA Acceptance for Bezuclastinib AdvSM Application
- Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
- Cogent Biosciences Enters Commercial Supply Agreement With Hovione FarmaCiencia
Cogent Biosciences Healthcare Stock: Key Questions Answered
Research dated 2026-09-13; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What is CGT-something and why would it work?
Cogent's lead candidate is a targeted inhibitor designed to block a specific genetic mutation. The company has selected patients with the mutation and is testing whether blocking the target leads to clinical benefit. Success would mean regulators approve the drug and physicians prescribe it for patients with the mutation. Failure means the target either does not work or the drug is unsafe.
When will Cogent have revenue?
Revenue depends on whether the lead program gains regulatory approval and whether the company maintains the commercial rights (or partnerships with a larger firm to commercialize). Timeline estimates suggest potential approval and launch are years away. Analysts forecast revenue beginning in later fiscal periods, but these estimates depend on clinical trial success, which is inherently uncertain.
Should I buy this stock if I think the drug will work?
Stock price will largely track clinical trial progress and cash runway. If you are confident the drug will work, the question is valuation: whether current market price reflects fair odds of success and reasonable upside if it does. Biotech valuations are volatile; a single setback can halve the stock, and a strong trial result can double it. Position sizing matters more than conviction.
What is the dilution risk if the company needs to raise capital?
If Cogent must issue equity before the lead program launches, current shareholders will be diluted by the percentage that new shares represent. The magnitude depends on how much capital the company needs and at what valuation it can raise. Investors should monitor cash balance and management guidance on future capital needs to anticipate dilution likelihood and timing.
What is the COGT stock price today?
The last price recorded on this page for Cogent Biosciences, Inc. (COGT) is $31.02, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the COGT price target?
The analyst consensus price target for Cogent Biosciences, Inc. (COGT) is $51.75 (range $45.00 to $55.00, median $53.50), per FMP data captured Oct 5, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Claude (claude-haiku-4-5) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (69 figures)
The 69 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
id.hq | SEC filing business address | 180 Third Avenue, 4TH Floor, Waltham, MA | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "275 Wyman Street, Waltham, MA, 02451, US". The FMP company description names Cambridge, Massachusetts as the headquarters; this page uses the address in this row. |
FMP — 61 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Nov 6, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.last | Latest provided price | $31.02 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T20:54:50.359Z. | |
px.change | Change on the day | -1.80% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $5.30B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:01.000Z. Captured from FMP at 2026-10-04T20:54:49.376Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | −$0.57 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $0 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.range52 | 52-week range | $13.78–$43.73 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | -37.99 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 1.17M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.31 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Andrew R. Robbins | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 258 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $0.00, net result −$72.27M; FY2022 revenue $0.00, net result −$140.24M; FY2023 revenue $0.00, net result −$192.41M; FY2024 revenue $0.00, net result −$255.86M; FY2025 revenue $0.00, net result −$328.94M | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.rev_mix | Reported revenue segments | Preclinical Research And Clinical Development $25.00M | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K | |
fin.q_table.depth.2026-06-30.rd_k | R&D — period end 2026-06-30 | $70.81M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.sga_k | SG&A — period end 2026-06-30 | $31.83M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.operating_result_k | FMP standardized operating result — period end 2026-06-30 | −$102.64M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.rd_k | R&D — period end 2026-03-31 | $75.36M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.sga_k | SG&A — period end 2026-03-31 | $28.24M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.operating_result_k | FMP standardized operating result — period end 2026-03-31 | −$103.61M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.rd_k | R&D — period end 2025-12-31 | $74.38M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $23.93M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | −$99.49M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.rd_k | R&D — period end 2025-09-30 | $68.99M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.sga_k | SG&A — period end 2025-09-30 | $14.37M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.operating_result_k | FMP standardized operating result — period end 2025-09-30 | −$83.36M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-08-10.revenue_estimated | Revenue · estimate — report date 2026-08-10 | $1,000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-10.eps_actual | EPS · reported — report date 2026-08-10 | −$0.5200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-10.eps_estimated | EPS · estimate — report date 2026-08-10 | −$0.5550 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-05.revenue_estimated | Revenue · estimate — report date 2026-05-05 | $500.00 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-05.eps_actual | EPS · reported — report date 2026-05-05 | −$0.5300 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-05.eps_estimated | EPS · estimate — report date 2026-05-05 | −$0.5300 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-17.eps_actual | EPS · reported — report date 2026-02-17 | −$0.5500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-17.eps_estimated | EPS · estimate — report date 2026-02-17 | −$0.5100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-07.eps_actual | EPS · reported — report date 2025-11-07 | −$0.5000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-07.eps_estimated | EPS · estimate — report date 2025-11-07 | −$0.5400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $792.30M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | −$77.27M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-30. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $244.26M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 9.96× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-06-30.operating_cash_flow_m | Operating cash flow — period end 2026-06-30 | −$77.27M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.operating_cash_flow_m | Operating cash flow — period end 2026-03-31 | −$86.88M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-30.capex_m | Capital expenditure (reported) — period end 2026-06-30 | −$370,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.capex_m | Capital expenditure (reported) — period end 2026-03-31 | −$450,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | −$79.10M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | −$810,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.operating_cash_flow_m | Operating cash flow — period end 2025-09-30 | −$64.29M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.capex_m | Capital expenditure (reported) — period end 2025-09-30 | −$60,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $45.00 – $55.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $51.75 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $53.50 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 15 transactions · 0 purchases, 2 sales, 13 other transactions · 7 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Aug 27, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.holders | Reporting holders | 336 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 317 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Fmr LLC — shares in provider snapshot | 25,681,174 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Blackrock, INC. — shares in provider snapshot | 17,352,646 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Vanguard Portfolio Management LLC — shares in provider snapshot | 8,072,411 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Vanguard Capital Management LLC — shares in provider snapshot | 7,412,330 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | State Street Corp — shares in provider snapshot | 6,964,919 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 3 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 4 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-16 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 7.79 · Piotroski F 2 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE -85.7% · ROA -38.1% · current ratio 15.14 | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 2 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 6.69× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $792.30M at Jun 30, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-02. Balance-sheet reference date: 2026-06-30. The inputs do not establish a single common source date for this ratio. |
earn.history.depth.2026-08-10.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS (−$0.5200) with the recorded estimate (−$0.5550) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 53 of 100 · Fair · pillars 39 / 59 / 47 / 30 / 70 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 53 (stored snapshot Oct 4, 2026) → 53 (current publication computed Oct 5, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-30. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-30.rd_k,fin.q_table.depth.2026-06-30.sga_k,fin.q_table.depth.2026-06-30.operating_result_k,fin.q_table.depth.2026-03-31.rd_k,fin.q_table.depth.2026-03-31.sga_k,fin.q_table.depth.2026-03-31.operating_result_k,fin.q_table.depth.2025-12-31.rd_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-09-30.rd_k,fin.q_table.depth.2025-09-30.sga_k,fin.q_table.depth.2025-09-30.operating_result_k. - Earnings-history note. Source series as of 2026-08-10. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-10.revenue_estimated,earn.history.depth.2026-08-10.eps_actual.comparison,earn.history.depth.2026-08-10.eps_actual,earn.history.depth.2026-08-10.eps_estimated,earn.history.depth.2026-05-05.revenue_estimated,earn.history.depth.2026-05-05.eps_actual,earn.history.depth.2026-05-05.eps_estimated,earn.history.depth.2026-02-17.eps_actual,earn.history.depth.2026-02-17.eps_estimated,earn.history.depth.2025-11-07.eps_actual,earn.history.depth.2025-11-07.eps_estimated. - Cash-flow note. Source series as of 2026-06-30. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-30.operating_cash_flow_m,fin.opcf.depth.2026-03-31.operating_cash_flow_m,fin.opcf.depth.2026-06-30.capex_m,fin.opcf.depth.2026-03-31.capex_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2025-12-31.capex_m,fin.opcf.depth.2025-09-30.operating_cash_flow_m,fin.opcf.depth.2025-09-30.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Cash runway cross-check (ours) | Years: 2.9; Method: cash and short-term investments of $792.3M at 2026-06-30 divided by the annualized rate at which operations and capital spending used cash ($271.9M per year); Reaches: 2029-05; Cash basis: cash and short-term investments; Cash: $792.30M; Annualized cash use: $271.90M Rate taken from operating cash flow less capital expenditure over the 8 most recent reported quarters, annualized.; Measured from operations, not from the change in the cash balance — a company that raised money during the window would otherwise appear to be burning less than it is.; Assumes that rate continues unchanged: it ignores announced cost reductions, financing already arranged and any change in spending.; Assumes the reported cash and short-term investments are realizable for funding operations; restrictions and timing of access are not established by these provider fields. Long-term investments are excluded.; It is a cross-check, not a forecast, and the company's own statement about its runway outranks it. | 2026-06-30 | COMPUTED | Computed from reported cash flow; assumptions stated |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Cash, investments and debt | Total debt: $244.26M; Liquidity basis: cash and short-term investments; Total liabilities: $302.16M; Cash and short-term investments: $792.30M; Cash and investments: $792.30M; Long-term investments: $0; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Trailing twelve-month ratio set | Quick ratio: 13.57; Current ratio: 13.57; Debt to equity: 0.46; Return on assets: -45.2%; Return on equity: -72.6% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Next earnings report | Date: 2026-11-06; EPS estimate: -$0.57 per share; Revenue estimate: $750,000 The date is our provider's estimate until the company confirms it. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) earnings calendar |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-13 | FMP | Financial Modeling Prep (FMP) analyst estimates |
| Recent SEC filings |
| 2026-09-02 | OFFICIAL | SEC EDGAR filer submissions |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Most recent Schedule 13D | Form: SC 13D/A; Filed: 2024-06-13 A Schedule 13D is filed by a holder of more than 5% who is not a passive investor. | 2024-06-13 | OFFICIAL | SEC EDGAR — SC 13D/A |
Data provided for informational purposes only.